Zylox-Tonbridge Acquires Medical Device Company in Germany

Hong Kong-listed Zylox-Tonbridge, focusing on peripheral and neurovascular intervention products and solutions, announced today that it has entered into a definitive acquisition agreement with German medical technology company Optimed Medizinische Instrumente GmbH (hereinafter referred to as "Optimed") to acquire Optimed in stages. Optimed is a company focused on the research, development, production, and sales of minimally invasive treatment medical devices globally. Under the terms of the agreement, Zylox-Tonbridge has the right to acquire all of the shares from Optimed's existing shareholders.

Optimed is a leading medical technology company specializing in minimally invasive vascular intervention and urology devices. For nearly three decades, Optimed has established an extensive sales and service network covering over 70 countries worldwide, and has built long-term relationships with clinicians and academic opinion leaders in Europe and other major markets.

Optimed boasts one of the most comprehensive portfolios in the peripheral venous stent market, including dedicated devices for the iliofemoral vein, iliac bifurcation, and inferior vena cava. Optimed's dedicated venous stents are supported by high-level clinical trials, such as the STEVECO trial, the first prospective, randomized, multi-center trial for chronic deep venous obstruction. This trial demonstrated that Optimed's stent treatment significantly improved patients' quality of life and clinical symptoms compared to conservative treatment.

The acquisition of Optimed will accelerate CardioFlow Medtech's global expansion and establish a unified platform encompassing R&D, manufacturing, and commercialization. By integrating the sales networks of both companies and leveraging Optimed's long-standing partnerships with European clinical experts, CardioFlow Medtech will be able to bring products to market more efficiently and expand its global footprint. Furthermore, the collaboration is expected to generate significant operational synergies, leveraging the production base in Germany to ensure the delivery of high-quality, reliable, and innovative medical solutions to both European and global markets. Upon completion of the transaction, CardioFlow Medtech will integrate its sales, marketing, and customer service teams with those of Optimed to form a unified global commercial organization. Rüdiger Hausherr will continue to serve as CEO of Optimed and will report to Dr. Zhaozhong, Chairman and CEO of CardioFlow Medtech.

Dr. Zhong Zhao, Chairman and CEO of Grandflow, stated: "This acquisition is a significant milestone in Grandflow's global strategy, enabling the company to leverage a broader European platform to accelerate global expansion. We warmly welcome Optimed into the Grandflow family and look forward to integrating our complementary strengths in product portfolio, manufacturing operations, and commercialization platforms to provide high-quality, innovative, and affordable solutions to more patients and doctors worldwide, while driving the company into its next phase of growth."

"For almost three decades, Optimed has worked closely with physicians and built a trusted brand in the fields of vascular and urology surgery. While Optimed has a solid position in the global market, customer needs and the rapid development of the healthcare industry mean that sticking to the old ways is no longer viable. Over the past few months, we have worked with Guichuang Tongqiao to develop a clear and consistent strategic vision. By combining Guichuang Tongqiao's strong R&D and manufacturing capabilities with Optimed's global business network, we are building a solid foundational platform to accelerate the next phase of growth and provide greater value to clinicians and patients worldwide."

Hans-Henning von Oertzen, Founder and Managing Partner at Westlake Partners, stated, "Since our investment in Optimed, we have worked closely with the team to expand the product portfolio, strengthen clinical partnerships, and extend its international reach, helping Optimed become a leader in minimally invasive vascular and urological solutions. Trireme Medical is a rapidly growing multinational medical technology company with deep roots in China and a highly regarded R&D, manufacturing, and global commercialization capability. We look forward to seeing the two companies partner together to seize new opportunities and collectively create a better future for physicians and patients worldwide."